CAS NO: | 1256388-51-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Ledipasvir (GS-5885) is an inhibitor of thehepatitis C virus NS5A, withEC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also aSARS-CoV3CLproinhibitor with anIC50of 1.62 μM[3]. | ||||||||||||||||
IC50& Target | EC50: 34 pM (GT1a), 4 pM (GT1b)[1] | ||||||||||||||||
体外研究 (In Vitro) | Ledipasvir has GT1a and 1b EC50values of 31 and 4 pM, respectively, and protein-adjusted EC50values of 210 pM (GT1a) and 27 pM (GT1b) and the intrinsic EC50of 39 is 310 fM for GT1a and 40 fM for GT1b. Ledipasvir is highly protein-bound both in human serum and in the cell-culture medium (containing 10% BSA) of the replicon assay[1]. Ledipasvir exhibits an EC50value of 141 nM against the JFH/3a-NS5A replicon[2]. | ||||||||||||||||
体内研究 (In Vivo) | Ledipasvir is remarkable not only on the basis of its high replicon potency but also on the basis of its low clearance, good bioavailability, and long half-lives in rat, dog, and monkey and low predicted clearance in human. The pharmacokinetics of Ledipasvir is measured in rats and dogs. Ledipasvir shows good half-lives (rat 1.83 ± 0.22 hr, dog 2.63 ± 0.18 hr) in plasma, low systemic clearance (CL), and moderate volumes of distribution (Vss) that are greater than total body water volume[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 889.00 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C49H54F2N8O6 | ||||||||||||||||
CAS 号 | 1256388-51-8 | ||||||||||||||||
中文名称 | 雷迪帕韦;来地帕韦 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(56.24 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|